Zafrens
Private Company
Funding information not available
Overview
Zafrens is pioneering a next-generation, high-throughput experimental platform that uniquely links phenotypic imaging with single-cell genomic sequencing at an unprecedented scale. Its core innovation, Z-Screen, uses nanofabrication to run millions of nanoliter-volume experiments on a benchtop instrument without robotics, compressing drug discovery timelines. The platform's universal workflow is applicable to small molecules, biologics, cell therapies, and gene therapies, with current efforts focused on internal small molecule discovery and T cell analysis. By generating massive, causally-linked multimodal datasets, Zafrens aims to unlock novel therapeutic insights and accelerate the development of all therapeutic modalities.
Technology Platform
Z-Screen: A nanofabricated platform replacing 96-well plates with 50,000-200,000 nanoliter wells containing a built-in mRNA sequencer. It enables simultaneous longitudinal imaging and single-cell sequencing (Active-seq) for millions of experiments per day on a benchtop, linking perturbations, phenotype, and genotype at scale.
Opportunities
Risk Factors
Competitive Landscape
Z-Screen is a first-of-its-kind integrated platform. It competes indirectly with leaders in high-throughput screening (e.g., PerkinElmer, Revvity), single-cell sequencing (10x Genomics, Parse Biosciences), and high-content imaging, but no competitor appears to offer the same seamless, high-scale pairing of longitudinal live-cell imaging with single-cell sequencing in a perturbational context.